Product Code Database
Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty, is a minimally invasive endovascular procedure used to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.
A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the stenosis blood vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. A stent may be inserted at the time of ballooning to ensure the vessel remains open, and the balloon is then deflated and withdrawn. Angioplasty has come to include all manner of Blood vessel interventions that are typically performed .
Coronary angioplasty is indicated for coronary artery diseases such as unstable angina, NSTEMI, STEMI and spontaneous coronary artery perforation. Percutaneous coronary intervention for stable coronary disease has been shown to significantly relieve symptoms such as angina, or chest pain, thereby improving functional limitations and quality of life.
The bypass versus angioplasty in a study of severe ischemia of the leg investigated infrainguinal vascular bypass first compared to angioplasty first in select patients with severe lower limb ischemia who were candidates for either procedure. In this study, angioplasty was associated with less short term morbidity compared with bypass surgery; however, long term outcomes favor bypass surgery.
Based on this study, the ACCF/AHA guidelines recommend balloon angioplasty only for patients with a life expectancy of 2 years or less or those who do not have an Vascular bypass available. For patients with a life expectancy greater than 2 of years life, or who have an autogenous vein, a bypass surgery could be performed first.
Percutaneous transluminal coronary angioplasty is contraindicated in patients with left main coronary artery disease, due to the risk of spasm of the left main coronary artery during the procedure. It is also not recommended if there is less than 70% stenosis of the coronary arteries, as stenosis is not hemodynamically significant below this level.
To treat a narrowing in a blood vessel, a wire is passed through the stenosis in the vessel and a Balloon catheter is passed over the wire (= OTW) and into the desired position. The positioning is verified by fluoroscopy and the balloon is inflated using water mixed with contrast dye to 75 to 500 times normal blood pressure (6 to 20 atmospheres), with most coronary angioplasties requiring less than 10 atmospheres. A stent may or may not also be placed.
At the conclusion of the procedure, the balloons, wires and catheters are removed and the vessel puncture site is treated either with direct pressure or a vascular closure device.
Transradial artery access and transfemoral artery access are two techniques for percutaneous coronary intervention. Transradial artery access is the technique of choice for management of acute coronary syndrome as it has significantly lower incidence of bleeding and vascular complications compared with the transfemoral artery approach. It also has a mortality benefit for high risk patients with acute coronary syndrome and who are at high risk of bleeding. Transradial artery access was also found to yield improved quality of life, as well as decreased healthcare costs and resources.
Angioplasty may also provide a less durable treatment for atherosclerosis and be more prone to restenosis relative to vascular bypass or coronary artery bypass grafting. Drug-eluting balloon angioplasty has significantly less restenosis, late lumen loss and target lesion revascularization at both short term and midterm follow-up compared to uncoated balloon angioplasty for femoropopliteal arterial occlusive disease. Although angioplasty of the femoropopliteal artery with paclitaxel-coated stents and balloons significantly reduces rates of vessel restenosis and target lesion revascularization, it was also found to have increased risk of death.
Atherectomy is an adjunctive therapy used for lesion preparation of calcified plaque before percutaneous coronary intervention. The goal of lesion preparation with atherectomy is to modify calcified plaque, which changes the lesion compliance and allows for adequate balloon and stent expansion in segments with heavily calcified lesions.
Atherectomy is a valuable adjunctive therapy for patients with coronary artery disease, particularly those with severely calcified lesions where traditional balloon angioplasty and stenting may be insufficient. Its success depends on the selection of appropriate devices and the operator’s expertise in managing the technical nuances to minimize complications. Studies have demonstrated that atherectomy can enhance procedural success rates and long-term outcomes in complex cases. However, further research and standardized protocols are needed to address challenges and expand its clinical applications effectively.
The catheter site is checked for bleeding and swelling and the heart rate and blood pressure are monitored to detect late rupture and hemorrhage. Post-procedure protocol also involves monitoring urinary output, cardiac symptoms, pain and other signs of systemic problems. Usually, patients receive medication that will relax them to protect the arteries against . Patients are typically able to walk within two to six hours following the procedure and return to their normal routine by the following week.
Angioplasty recovery consists of avoiding physical activity for several days after the procedure. Patients are advised to avoid heavy lifting and strenuous activities for a week. Page last reviewed: 28/08/2018 Patients will need to avoid physical stress or prolonged sport activities for a maximum of two weeks after a delicate balloon angioplasty.
After the initial two week recovery phase, most angioplasty patients can begin to safely return to low-level exercise. A graduated exercise program is recommended whereby patients initially perform several short bouts of exercise each day, progressively increasing to one or two longer bouts of exercise. As a precaution, all structured exercise should be cleared by a cardiologist before commencing. Exercise-based rehabilitation following percutaneous coronary intervention has shown improvement in recurrent angina, total exercise time, ST-segment decline, and maximum exercise tolerance.
Patients who experience swelling, bleeding or pain at the insertion site, develop fever, feel faint or weak, notice a change in temperature or color in the arm or leg that was used or have shortness of breath or chest pain should immediately seek medical advice.
Patients with stents are usually prescribed dual antiplatelet therapy which consists of a P2Y12 inhibitor, such as clopidogrel, which is taken at the same time as acetylsalicylic acid (aspirin). Dual antiplatelet therapy (DAPT) is recommended for 1 month following bare metal stent placement, for 3 months following a second generation drug-eluting stent placement, and for 6–12 months following a first generation drug-eluting stent placement. Dual antiplatelet therapy's properties are intended to prevent blood clots; however, they increase the risk of bleeding, so it is important to consider each patient's preferences, cardiac conditions, and bleeding risk when determining the duration of its treatment. Another important consideration is that concomitant use of clopidogrel and proton-pump inhibitors following coronary angiography is associated with significantly higher adverse cardiovascular complications such as major adverse cardiovascular events, stent thrombosis and myocardial infarction.
The first percutaneous coronary angioplasty on an awake patient was performed in Zurich by the German cardiologist Andreas Gruentzig on September 16, 1977.
The first percutaneous coronary angioplasties in the United States were performed on the same day (March 1, 1978) by Simon H. Stertzer at Lenox Hill Hospital in New York and Richard K. Myler at St. Mary's Hospital in San Francisco. During the previous year, also at St. Mary's Hospital in San Francisco, Myler and Gruentzig had performed dilatations in the setting of bypass surgery to test the catheter concept before Gruentzig performed the first percutaneous transluminal coronary angioplasty in his catheterization lab in Zurich.
The initial form of angioplasty was 'plain old balloon angioplasty' without stenting, until the invention of bare metal stents in the mid-1980s to prevent the abrupt closure that sometimes occurred plain old balloon angioplasty.
Bare metal stents were found to cause in-stent restenosis as a result of neointimal hyperplasia and stent thrombosis, which led to the invention of drug-eluting stents with anti-proliferative drugs to combat in-stent restenosis.
The first coronary angioplasty with a drug delivery stent system was performed by Stertzer and Luis de la Fuente, at the Instituto Argentino de Diagnóstico y Tratamiento (English: Argentina Institute of Diagnosis and Treatment) in Buenos Aires, in 1999.
Ingemar Henry Lundquist invented the over-the-wire balloon catheter that is now used in the majority of angioplasty procedures in the world.
A subset of angioplasty, known as excimer laser coronary angioplasty, uses to remove small amounts of tissue, including undilatable and uncrossable lesions, in the artery in order to allow the balloon to more effectively compress plaque into the artery walls. Such work was first developed in 1984 following earlier work in 1980–1983, when Rangaswamy Srinivasan, Samuel Blum and James J. Wynne at IBM's T. J. Watson Research Center observed the effect of the ultraviolet excimer laser on biological materials. Intrigued, they investigated further, finding that the laser made clean, precise cuts that would be ideal for delicate surgeries. This resulted in a fundamental patent and Srinivasan, Blum and Wynne were elected to the National Inventors Hall of Fame in 2002. In 2012, the team members were honored with National Medal of Technology and Innovation by the President Barack Obama for their work related to the excimer laser. Robert Ginsburg deployed the first used of excimer laser coronary angioplasty in 1984 on a patient with severe stenosis of the deep femoral artery and a threatened limb.
|
|
